Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Candida glabrata UDP-galactose transporter homolog 1 (HUT1), partial CSB-YP763761CZI
CSB-EP763761CZI
CSB-BP763761CZI
CSB-MP763761CZI
CSB-EP763761CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Protein transport protein SEC23-1 (SEC231), partial CSB-YP763762CZI
CSB-EP763762CZI
CSB-BP763762CZI
CSB-MP763762CZI
CSB-EP763762CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Transcriptional acticator POG1 (POG1), partial CSB-YP763763CZI
CSB-EP763763CZI
CSB-BP763763CZI
CSB-MP763763CZI
CSB-EP763763CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata DNA repair and recombination protein RAD52 (RAD52), partial CSB-YP763764CZI
CSB-EP763764CZI
CSB-BP763764CZI
CSB-MP763764CZI
CSB-EP763764CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Required for respiratory growth protein 1, mitochondrial (RRG1) CSB-YP763765CZI
CSB-EP763765CZI
CSB-BP763765CZI
CSB-MP763765CZI
CSB-EP763765CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata DNA replication complex GINS protein SLD5 (SLD5) CSB-YP763766CZI
CSB-EP763766CZI
CSB-BP763766CZI
CSB-MP763766CZI
CSB-EP763766CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Diphthamide biosynthesis protein 1 (DPH1) CSB-YP763767CZI
CSB-EP763767CZI
CSB-BP763767CZI
CSB-MP763767CZI
CSB-EP763767CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata rRNA-processing protein EFG1 (EFG1) CSB-YP763768CZI
CSB-EP763768CZI
CSB-BP763768CZI
CSB-MP763768CZI
CSB-EP763768CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Enolase 1 (ENO1) CSB-YP763769CZI
CSB-EP763769CZI
CSB-BP763769CZI
CSB-MP763769CZI
CSB-EP763769CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Protein RMD9, mitochondrial (RMD9), partial CSB-YP763770CZI
CSB-EP763770CZI
CSB-BP763770CZI
CSB-MP763770CZI
CSB-EP763770CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Chromosome segregation in meiosis protein 3 (CSM3) CSB-YP763771CZI
CSB-EP763771CZI
CSB-BP763771CZI
CSB-MP763771CZI
CSB-EP763771CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata ATP-dependent RNA helicase DBP9 (DBP9), partial CSB-YP763772CZI
CSB-EP763772CZI
CSB-BP763772CZI
CSB-MP763772CZI
CSB-EP763772CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Protoheme IX farnesyltransferase, mitochondrial (COX10), partial CSB-YP763773CZI
CSB-EP763773CZI
CSB-BP763773CZI
CSB-MP763773CZI
CSB-EP763773CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Type 1 phosphatases regulator YPI1 (YPI1) CSB-YP763774CZI
CSB-EP763774CZI
CSB-BP763774CZI
CSB-MP763774CZI
CSB-EP763774CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata V-type proton ATPase 16 kDa proteolipid subunit 2 (VMA11), partial CSB-YP763775CZI1
CSB-EP763775CZI1
CSB-BP763775CZI1
CSB-MP763775CZI1
CSB-EP763775CZI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata tRNA pseudouridine synthase 1 (PUS1), partial CSB-YP763776CZI
CSB-EP763776CZI
CSB-BP763776CZI
CSB-MP763776CZI
CSB-EP763776CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata pH-response transcription factor pacC/RIM101 (RIM101), partial CSB-YP763777CZI
CSB-EP763777CZI
CSB-BP763777CZI
CSB-MP763777CZI
CSB-EP763777CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Mitochondrial group I intron splicing factor CCM1 (CCM1), partial CSB-YP763778CZI
CSB-EP763778CZI
CSB-BP763778CZI
CSB-MP763778CZI
CSB-EP763778CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Palmitoyltransferase PFA4 (PFA4), partial CSB-YP763779CZI1
CSB-EP763779CZI1
CSB-BP763779CZI1
CSB-MP763779CZI1
CSB-EP763779CZI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata NEDD8-conjugating enzyme UBC12 (UBC12) CSB-YP763780CZI
CSB-EP763780CZI
CSB-BP763780CZI
CSB-MP763780CZI
CSB-EP763780CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>